- Record: found
- Abstract: found
- Article: not found
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.
J A Freeman
1 ,
A J Thompson ,
R Fitzpatrick ,
M Hutchinson ,
C Miltenburger ,
K Beckmann ,
F Dahlke ,
L Kappos ,
C Polman ,
C Pozzilli
Nov 27 2001
Read this article at
ScienceOpenPubMed
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The recent randomized, controlled trial of interferon-beta1b (IFN-beta1b) in 718 patients with secondary progressive MS (SP-MS) demonstrated a significant effect on the development of disability as evaluated by the physician. Its effect on patient-reported health-related quality of life (HrQoL) is reported herein.